<DOC>
	<DOCNO>NCT02429687</DOCNO>
	<brief_summary>Investigators conduct trial determine whether paclitaxel cisplatin ( PT ) curative effect less adverse effect bleomycin , etoposide cisplatin ( BEP ) among newly diagnose malignant ovarian germ cell tumor patient surgery .</brief_summary>
	<brief_title>TC BEP Treating Patients With Malignant Ovarian Germ Cell Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : To assess activity paclitaxel carboplatin respect progression free survival ( use bleomycin , etoposide , cisplatin [ BEP ] reference ) newly diagnose malignant ovarian germ cell tumor . SECONDARY OBJECTIVES : 1 . To estimate toxicity paclitaxel carboplatin , bleomycin , etoposide , cisplatin patient population . 2 . To estimate overall survival paclitaxel carboplatin relative BEP . 3 . To evaluate response rate subset patient measurable disease . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . ARM 1 : Patients receive paclitaxel IV 3 hour carboplatin IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . ARM 2 : Patients receive bleomycin IV per week , etoposide IV daily day 1-5 , cisplatin IV day 1-5 . Treatment repeat every 21 day 3 4* course absence disease progression unacceptable toxicity . NOTE : *Patients good risk 3 course poor risk 4 course . Patients undergo blood sample collection baseline periodically study laboratory biomarker analysis . After completion study therapy , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>Age≤65 year ; female , Chinese woman ; Histologically confirm ovarian stromal tumor , include follow cell type : Granulosa cell tumor Granulosa celltheca cell tumor SertoliLeydig cell tumor ( androblastoma ) Steroid ( lipid ) cell tumor Gynandroblastoma Unclassified sex cordstromal tumor Sex cord tumor annular tubule Newly diagnose , stage IIAIVB disease ; Has undergone initial surgery ( diagnosis , stag , cytoreduction ) within past 8 week . May may measurable residual disease . Laboratory test : WBC≥4×10 ( 9 ) /L , NEU≥2×10 ( 9 ) /L , PLT≥80×10 ( 9 ) /L , serum bilirubin≤ 1.5 time upper limit normal , transaminase≤ 1.5 time upper limit normal , BUN , Cr≤ normal Performance status : Karnofsky score≥60 ; Provide write informed consent . With severe uncontrolled internal disease , unable receive surgery and/or unsuitable chemotherapy ; History organ transplantation , immune disease ; History serious mental illness , history brain dysfunction ; Drug abuse history drug abuse ; Suffering malignancy ; Concurrently participate clinical trial Unable unwilling sign informed consent ; Unable unwilling abide protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>